Earnings Feed
Start Free
Biofrontera Inc.·4

Mar 6, 9:31 PM ET

Luebbert Hermann 4

Research Summary

AI-generated summary

Updated

Biofrontera (BFRI) CEO Luebbert Converts RSUs, Receives 250,000 Awards

What Happened

  • Luebbert Hermann, CEO & Chairman of Biofrontera (BFRI), had vested restricted stock units convert into 137,500 shares on March 5, 2026 (derivative exercise/conversion) and those 137,500 shares are shown as disposed on the same date at $0.00.
  • Separately, on March 4, 2026 he was awarded two restricted stock unit grants of 125,000 shares each (250,000 RSUs total) for no consideration (reported price $0.00). These awards are derivative awards (not immediate common‑stock purchases) and the filing reports no cash value for the grants or the listed dispositions.

Key Details

  • Transaction dates and reported prices:
    • 2026-03-04: Award of 125,000 RSUs @ $0.00 (x2 = 250,000 RSUs total).
    • 2026-03-05: Conversion/exercise of 137,500 RSUs into common stock (reported as acquired) and 137,500 shares disposed on 03-05 at $0.00 (derivative transaction code M).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Notable footnotes from the filing:
    • RSUs convert 1-for-1 into common stock (F1).
    • The new RSUs were granted for no consideration and vest in two equal annual installments beginning March 4, 2027; each vested RSU may be settled in shares, cash, or a combination within 60 days (F2, F3).
    • The 137,500 settled on March 5, 2026 appears to be a tranche from a July 12, 2024 grant (275,000 RSUs originally; two tranches) that was settled on March 5, 2026 per footnote (F5).
  • Timeliness: Form 4 filed 2026-03-06 for transactions reported as of 2026-03-04 — filing appears timely (no late filing indicated).

Context

  • The March 4 awards are RSUs (awards), not open‑market purchases — these are compensation grants subject to future vesting and settlement rules, and do not by themselves indicate immediate insider buying.
  • The March 5 conversion and simultaneous reported disposition of 137,500 shares were reported at $0.00; the filing’s footnotes state the company may settle vested RSUs in shares, cash, or a combination within 60 days, and note the tranche was settled on March 5, 2026. That suggests the conversion/settlement was processed per the award terms rather than a typical open‑market sale.